Gonadorelin

Gonadorelin is a synthetic decapeptide identical in structure to the naturally occurring gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). This hypothalamic hormone is the master regulator of the reproductive endocrine axis, controlling the release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary gland. The natural GnRH was first isolated and characterized by Andrew Schally and Roger Guillemin, work that earned them the 1977 Nobel Prize in Physiology or Medicine.

In its physiological role, GnRH is released in a pulsatile fashion from the hypothalamus, and this pulsatile pattern is critical for maintaining normal reproductive function. Continuous, non-pulsatile administration of GnRH or its analogs paradoxically leads to downregulation and desensitization of pituitary GnRH receptors, ultimately suppressing gonadotropin release. This paradoxical effect forms the basis for the therapeutic use of GnRH agonists in conditions where sex hormone suppression is desired.

Gonadorelin is primarily used as a diagnostic agent in the GnRH stimulation test, which evaluates the functional capacity of the anterior pituitary gonadotropes. In this test, a bolus injection of gonadorelin is administered and subsequent LH and FSH responses are measured. The test helps distinguish between hypothalamic and pituitary causes of hypogonadism and is valuable in the workup of delayed puberty, amenorrhea, and other reproductive disorders.

Therapeutically, pulsatile gonadorelin delivered via a portable infusion pump has been used to restore fertility in patients with hypothalamic amenorrhea or hypogonadotropic hypogonadism. This approach mimics the natural pulsatile release of GnRH and can successfully induce ovulation or spermatogenesis in appropriately selected patients.